Park Ha Biological Technology Co., Ltd. (PHH) Financials
Newest figures come from the 10-K for FY2025, filed May 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PHH SEC filings page.
Park Ha Biological Technology Co., Ltd. (PHH) reported $2.5M in revenue for fiscal year 2025, up 6.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Gross margins remain exceptional, but a FY2025 overhead surge overwhelmed them and left operations barely cash-generative.
Gross margin edged up to94.4% in FY2025 while operating margin fell to-956.5% ; the earnings collapse therefore occurred below gross profit, not in reported product costs. SG&A reached$25.5M against revenue of$2.5M , making overhead the central operating constraint.
FY2025 reported a net loss of
The 2025 current ratio was 2.9x and debt-to-equity was 0.5x, a less leveraged posture than the prior year. Yet financing cash flow of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Park Ha Biological Technology Co., Ltd.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Park Ha Biological Technology Co., Ltd.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 7/100.
Park Ha Biological Technology Co., Ltd.'s revenue grew 6.0% year-over-year to $2.5M, a solid pace of expansion. This earns a growth score of 35/100.
Park Ha Biological Technology Co., Ltd. has a moderate D/E ratio of 0.49. This balance of debt and equity financing earns a leverage score of 61/100.
With a current ratio of 2.92, Park Ha Biological Technology Co., Ltd. holds $2.92 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 77/100.
While Park Ha Biological Technology Co., Ltd. generated $86K in operating cash flow, capex of $89K consumed most of it, leaving -$3K in free cash flow. This results in a low score of 70/100, reflecting heavy capital investment rather than weak cash generation.
Park Ha Biological Technology Co., Ltd. posts a -609.9% return on equity (ROE), meaning it loses $610 for every $100 of shareholders' equity. This results in a returns score of 6/100. This is down from 31.8% the prior year.
Park Ha Biological Technology Co., Ltd. scores -14.45, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($11.3M) relative to total liabilities ($2.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Park Ha Biological Technology Co., Ltd. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Park Ha Biological Technology Co., Ltd. reported a net loss of $24.4M while generating $86K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Park Ha Biological Technology Co., Ltd. reported an operating loss of $24.1M against $41 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Park Ha Biological Technology Co., Ltd. held $3.8M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
PHH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
PHH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q2'256-K | Q4'2410-K | Q4'23 |
|---|---|---|---|---|
| Total Assets | $6.0M+93.1% | $5.8M | $3.1M+36.1% | $2.3M |
| Current Assets | $5.5M+93.4% | $5.6M | $2.8M+30.7% | $2.2M |
| Cash & Equivalents | $3.8M+591.8% | $1.4M | $547K-47.0% | $1.0M |
| Inventory | $75K+5.2% | $66K | $71K-25.4% | $96K |
| Accounts Receivable | $256K-22.7% | $123K | $331K-8.5% | $362K |
| Total Liabilities | $2.0M+24.1% | $1.6M | $1.6M+25.9% | $1.3M |
| Current Liabilities | $1.9M+23.4% | $1.5M | $1.5M+22.7% | $1.2M |
| Non-Current Liabilities | $76K+43.9% | $63K | $53K+455.7% | $9K |
| Total Equity | $4.0M+165.2% | $4.3M | $1.5M+48.8% | $1.0M |
| Retained Earnings | -$24.2M-8996.0% | -$19.6M | $272K+358.3% | -$105K |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill, Long-Term Debt.
PHH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
PHH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Park Ha Biological Technology Co., Ltd. PHH | FY2025 | $2.5M | -$24.4M | N/A | $11.3M | 43/100 |
| Raytech Holding Limited RAY | FY2026 | $18.2M | $2.1M | 11.7% | $16.4M | 61/100 |
| United-Guardian, Inc. UG | FY2025 | $10.5M | $2.1M | 20.0% | $31.4M | 76/100 |
| Tantech Holdings Ltd. TANH | FY2025 | $38.4M | -$31.0M | -80.9% | $9.1M | 36/100 |
| Grove Collaborative Holdings, Inc. GROV | FY2025 | $173.7M | -$11.7M | -6.7% | $41.8M | 35/100 |
| Big Tree Cloud Holdings Limited DSY | FY2025 | $2.6M | -$32.5M | N/A | $15.5M | 8/100 |
Where Park Ha Biological Technology Co., Ltd. Ranks
Frequently Asked Questions
What is Park Ha Biological Technology Co., Ltd.'s annual revenue?
Park Ha Biological Technology Co., Ltd. (PHH) reported $2.5M in total revenue for fiscal year 2025. This represents a 6.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Park Ha Biological Technology Co., Ltd.'s revenue growing?
Park Ha Biological Technology Co., Ltd. (PHH) revenue grew by 6.0% year-over-year, from $2.4M to $2.5M in fiscal year 2025.
Is Park Ha Biological Technology Co., Ltd. profitable?
No, Park Ha Biological Technology Co., Ltd. (PHH) reported a net income of -$24.4M in fiscal year 2025.
What is Park Ha Biological Technology Co., Ltd.'s EBITDA?
Park Ha Biological Technology Co., Ltd. (PHH) had EBITDA of -$24.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Park Ha Biological Technology Co., Ltd.'s gross margin?
Park Ha Biological Technology Co., Ltd. (PHH) had a gross margin of 94.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Park Ha Biological Technology Co., Ltd.'s return on equity (ROE)?
Park Ha Biological Technology Co., Ltd. (PHH) has a return on equity of -609.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Park Ha Biological Technology Co., Ltd.'s free cash flow?
Park Ha Biological Technology Co., Ltd. (PHH) recorded an outflow of $3K in free cash flow during fiscal year 2025. This represents a -100.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Park Ha Biological Technology Co., Ltd.'s operating cash flow?
Park Ha Biological Technology Co., Ltd. (PHH) generated $86K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Park Ha Biological Technology Co., Ltd.'s total assets?
Park Ha Biological Technology Co., Ltd. (PHH) had $6.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Park Ha Biological Technology Co., Ltd.'s capital expenditures?
Park Ha Biological Technology Co., Ltd. (PHH) invested $89K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Park Ha Biological Technology Co., Ltd. spend on research and development?
Park Ha Biological Technology Co., Ltd. (PHH) invested $238K in research and development during fiscal year 2025.
What is Park Ha Biological Technology Co., Ltd.'s current ratio?
Park Ha Biological Technology Co., Ltd. (PHH) had a current ratio of 2.92 as of fiscal year 2025, which is generally considered healthy.
What is Park Ha Biological Technology Co., Ltd.'s debt-to-equity ratio?
Park Ha Biological Technology Co., Ltd. (PHH) had a debt-to-equity ratio of 0.49 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Park Ha Biological Technology Co., Ltd.'s return on assets (ROA)?
Park Ha Biological Technology Co., Ltd. (PHH) had a return on assets of -409.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Park Ha Biological Technology Co., Ltd.'s Altman Z-Score?
Park Ha Biological Technology Co., Ltd. (PHH) has an Altman Z-Score of -14.45, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Park Ha Biological Technology Co., Ltd.'s Piotroski F-Score?
Park Ha Biological Technology Co., Ltd. (PHH) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Park Ha Biological Technology Co., Ltd.'s earnings high quality?
Park Ha Biological Technology Co., Ltd. (PHH) reported a net loss of $24.4M while generating $86K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Park Ha Biological Technology Co., Ltd. cover its interest payments?
Park Ha Biological Technology Co., Ltd. (PHH) reported an operating loss of $24.1M against $41 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Park Ha Biological Technology Co., Ltd.?
Park Ha Biological Technology Co., Ltd. (PHH) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.